ライフサイエンスコーパス: posttransplant lymphoproliferative disease

1 D4+ T cells reflects HVL patients at risk of posttransplant lymphoproliferative disease.

2 We had no cases of posttransplant lymphoproliferative disease.

3 Burkitt's lymphoma, Hodgkin's lymphoma, and posttransplant lymphoproliferative disease.

4 ew the clinical and pathological spectrum of posttransplant lymphoproliferative disease.

5 as not been previously reported as a form of posttransplant lymphoproliferative disease.

6 ed with an increased risk for development of posttransplant lymphoproliferative disease.

7 One patient in each group developed posttransplant lymphoproliferative disease.

8 may lead to potentially fatal EBV-associated posttransplant lymphoproliferative disease.

9 patients developed hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin

10 allogeneic CTL lines to treat EBV-associated posttransplant lymphoproliferative disease, a response r

11 We discuss this unique form of posttransplant lymphoproliferative disease and briefly r

12 ve Hodgkin disease but not in EBV-associated posttransplant lymphoproliferative disease and Hodgkin d

13 e first steps of in vivo immune control over posttransplant lymphoproliferative disease and lymphomas

14 tive for Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease and melanoma.

15 led lesions of Epstein-Barr virus-associated posttransplant lymphoproliferative disease and was chara

16 transplantation, (vii) graft disease, (viii) posttransplant lymphoproliferative disease, and (ix) sto

17 nt diabetes; 0.2%, avascular necrosis; 0.2%, posttransplant lymphoproliferative disease; and 0%, poly

18 nd reduce the risk of adverse events such as posttransplant lymphoproliferative disease are discussed

19 sia (ALH), that is pathologically similar to posttransplant lymphoproliferative disease associated wi

20 No patient developed posttransplant lymphoproliferative disease, but 22 patie

21 Posttransplant lymphoproliferative disease can be treate

22 er LT for advanced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal

23 associated with an increased risk of CMV or posttransplant lymphoproliferative disease compared with

24 Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) co

25 The fourteen patients with infections/posttransplant lymphoproliferative disease had a mean AT

26 Treatment of posttransplant lymphoproliferative disease has been augm

27 virus disease, graft-versus-host disease, or posttransplant lymphoproliferative disease has been obse

28 ic HCC and other tumors and various forms of posttransplant lymphoproliferative disease have occurred

29 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative disease have standard

30 ed with several human malignancies including posttransplant lymphoproliferative disease in immunosupp

31 BV), as is demonstrated by the occurrence of posttransplant lymphoproliferative disease in immunosupp

32 The incidence of posttransplant lymphoproliferative disease in patients r

33 ased risk of Epstein-Barr virus (EBV)-driven posttransplant lymphoproliferative disease, is an import

34 pisodes of allograft rejection, incidence of posttransplant lymphoproliferative disease or coronary a

35 te with clinical confounders or a history of posttransplant lymphoproliferative disease or Epstein-Ba

36 Ten patients had no previous diagnosis of posttransplant lymphoproliferative disease (PT-LPD), whi

37 This study describes the development of posttransplant lymphoproliferative disease (PTLD) after

38 Posttransplant lymphoproliferative disease (PTLD) after

39 is considered to be a major risk factor for posttransplant lymphoproliferative disease (PTLD) and AI

40 t survival, episodes of rejection as well as posttransplant lymphoproliferative disease (PTLD) and gr

41 ays an important role in the pathogenesis of posttransplant lymphoproliferative disease (PTLD) by per

42 EBV) DNA titers more than 1000 copies/mL and posttransplant lymphoproliferative disease (PTLD) develo

43 non-White ethnicity (p = 0.014) and previous posttransplant lymphoproliferative disease (PTLD) diagno

44 as to determine the incidence and hazard for posttransplant lymphoproliferative disease (PTLD) in a s

45 have previously reported a 10% incidence of posttransplant lymphoproliferative disease (PTLD) in ped

46 Posttransplant lymphoproliferative disease (PTLD) is a c

47 Epstein-Barr virus-associated posttransplant lymphoproliferative disease (PTLD) is a l

48 Posttransplant lymphoproliferative disease (PTLD) is a m

49 Posttransplant lymphoproliferative disease (PTLD) is a s

50 Posttransplant lymphoproliferative disease (PTLD) is a s

51 Posttransplant lymphoproliferative disease (PTLD) is a s

52 nosis of Epstein-Barr Virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD) is imp

53 the subsequent development of EBV-associated posttransplant lymphoproliferative disease (PTLD) is the

54 Optimal therapy for posttransplant lymphoproliferative disease (PTLD) remain

55 Optimal management of posttransplant lymphoproliferative disease (PTLD) remain

56 Posttransplant lymphoproliferative disease (PTLD) remain

57 The incidence, risk factors, and outcome of posttransplant lymphoproliferative disease (PTLD) were e

58 Epstein-Barr virus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD), and E

59 gnancies, including Burkitt's lymphoma (BL), posttransplant lymphoproliferative disease (PTLD), nasop

60 n increased risk of cytomegalovirus (CMV) or posttransplant lymphoproliferative disease (PTLD), we ex

61 s been linked to several diseases, including posttransplant lymphoproliferative disease (PTLD), which

62 elated primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD).

63 Transplant recipients are at risk of posttransplant lymphoproliferative disease (PTLD).

64 hat was lost 4 months after implantation for posttransplant lymphoproliferative disease (PTLD).

65 d to treat Epstein Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).

66 isodes, cytomegalovirus (CMV) infection, and posttransplant lymphoproliferative disease (PTLD).

67 ce of rejection and/or gastrointestinal (GI) posttransplant lymphoproliferative disease (PTLD).

68 mortality following lung transplantation is posttransplant lymphoproliferative disease (PTLD).

69 l load after the diagnosis of EBV-associated posttransplant lymphoproliferative disease (PTLD).

70 have been used clinically in the therapy of posttransplant lymphoproliferative disease (PTLD).

71 V) plays a major role in the pathogenesis of posttransplant lymphoproliferative disease (PTLD).

72 Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a seq

73 ad, EBV serology, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or sym

74 virus, BK virus, and Epstein-Barr virus) and posttransplant lymphoproliferative disease remained low.

75 gnized cytotoxic T-lymphocyte epitopes in 25 posttransplant lymphoproliferative disease specimens fro

76 antation (OLT) one of the patients developed posttransplant lymphoproliferative disease, successfully

77 target Epstein-Barr virus strains present in posttransplant lymphoproliferative disease tumors.

78 e: unknown (seven), poor compliance (three), posttransplant lymphoproliferative disease, (two), hepat

79 The incidence of posttransplant lymphoproliferative disease was equal in

80 EBV-related posttransplant lymphoproliferative disease was not obser

81 One (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, whi

82 The boy developed posttransplant lymphoproliferative disease, which resolv

83 (five Hodgkin's-like and one Burkitt's-like posttransplant lymphoproliferative disease) with restric

84 graft disease, (viii) chronic illness, (ix) posttransplant lymphoproliferative disease, (x) intracta